Anna C Calkin1, Stephen D Lee1, Jason Kim1, Caroline M W Van Stijn1, Xiao-Hui Wu1, Aldons J Lusis1, Cynthia Hong1, Rajendra I Tangirala1, Peter Tontonoz2. 1. From the Departments of Pathology and Laboratory Medicine (A.C.C., S.D.L., X.-H.W., C.H., P.T.), Department of Medicine, Division of Endocrinology (J.K., C.M.W.V.S., R.I.T.), Department of Medicine, Division of Cardiology (X.-H.W., A.J.L.), and Departments of Human Genetics and Microbiology Immunology and Molecular Genetics (A.J.L.), David Geffen School of Medicine, University of California, Los Angeles; Howard Hughes Medical Institute, Los Angeles, CA (A.C.C., S.D.L., C.H., P.T.); and Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia (A.C.C.). 2. From the Departments of Pathology and Laboratory Medicine (A.C.C., S.D.L., X.-H.W., C.H., P.T.), Department of Medicine, Division of Endocrinology (J.K., C.M.W.V.S., R.I.T.), Department of Medicine, Division of Cardiology (X.-H.W., A.J.L.), and Departments of Human Genetics and Microbiology Immunology and Molecular Genetics (A.J.L.), David Geffen School of Medicine, University of California, Los Angeles; Howard Hughes Medical Institute, Los Angeles, CA (A.C.C., S.D.L., C.H., P.T.); and Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia (A.C.C.). ptontonoz@mednet.ucla.edu.
Abstract
RATIONALE: The E3 ubiquitin ligase inducible degrader of the low-density lipoprotein receptor (IDOL) triggers lysosomal degradation of the low-density lipoprotein receptor. The tissue-specific effects of the IDOL pathway on plasma cholesterol and atherosclerosis have not been examined. OBJECTIVE: Given that the liver is the primary determinant of plasma cholesterol levels, we sought to examine the consequence of effect of chronic liver-specific expression of a dominant-active form of IDOL in mice. METHODS AND RESULTS: We expressed a degradation-resistant, dominant-active form of IDOL (super IDOL [sIDOL]) in C57Bl/6J mice from the liver-specific albumin promoter (L-sIDOL transgenics). L-sIDOL mice were fed a Western diet for 20 or 30 weeks and then analyzed for plasma lipid levels and atherosclerotic lesion formation. L-sIDOL mice showed dramatic reductions in hepatic low-density lipoprotein receptor protein and increased plasma low-density lipoprotein cholesterol levels on both chow and Western diets. Moreover, L-sIDOL mice developed marked atherosclerotic lesions when fed a Western diet. Lesion formation in L-sIDOL mice was more robust than in apolipoprotein E*3 Leiden mice and did not require the addition of cholate to the diet. Western diet-fed L-sIDOL mice had elevated expression of liver X receptor target genes and proinflammatory genes in their aortas. CONCLUSIONS: Liver-specific expression of dominant-active IDOL is associated with hypercholesterolemia and a marked elevation in atherosclerotic lesions. Our results show that increased activity of the IDOL pathway in the liver can override other low-density lipoprotein receptor regulatory pathways leading to cardiovascular disease. L-sIDOL mice are a robust, dominantly inherited, diet-inducible model for the study of atherosclerosis.
RATIONALE: The E3 ubiquitin ligase inducible degrader of the low-density lipoprotein receptor (IDOL) triggers lysosomal degradation of the low-density lipoprotein receptor. The tissue-specific effects of the IDOL pathway on plasma cholesterol and atherosclerosis have not been examined. OBJECTIVE: Given that the liver is the primary determinant of plasma cholesterol levels, we sought to examine the consequence of effect of chronic liver-specific expression of a dominant-active form of IDOL in mice. METHODS AND RESULTS: We expressed a degradation-resistant, dominant-active form of IDOL (super IDOL [sIDOL]) in C57Bl/6J mice from the liver-specific albumin promoter (L-sIDOL transgenics). L-sIDOL mice were fed a Western diet for 20 or 30 weeks and then analyzed for plasma lipid levels and atherosclerotic lesion formation. L-sIDOL mice showed dramatic reductions in hepatic low-density lipoprotein receptor protein and increased plasma low-density lipoprotein cholesterol levels on both chow and Western diets. Moreover, L-sIDOL mice developed marked atherosclerotic lesions when fed a Western diet. Lesion formation in L-sIDOL mice was more robust than in apolipoprotein E*3 Leiden mice and did not require the addition of cholate to the diet. Western diet-fed L-sIDOL mice had elevated expression of liver X receptor target genes and proinflammatory genes in their aortas. CONCLUSIONS: Liver-specific expression of dominant-active IDOL is associated with hypercholesterolemia and a marked elevation in atherosclerotic lesions. Our results show that increased activity of the IDOL pathway in the liver can override other low-density lipoprotein receptor regulatory pathways leading to cardiovascular disease. L-sIDOL mice are a robust, dominantly inherited, diet-inducible model for the study of atherosclerosis.
Authors: Sean B Joseph; Elaine McKilligin; Liming Pei; Michael A Watson; Alan R Collins; Bryan A Laffitte; Mingyi Chen; Grace Noh; Joanne Goodman; Graham N Hagger; Jonathan Tran; Tim K Tippin; Xuping Wang; Aldons J Lusis; Willa A Hsueh; Ronald E Law; Jon L Collins; Timothy M Willson; Peter Tontonoz Journal: Proc Natl Acad Sci U S A Date: 2002-05-28 Impact factor: 11.205
Authors: Daphna Weissglas-Volkov; Anna C Calkin; Teresa Tusie-Luna; Janet S Sinsheimer; Noam Zelcer; Laura Riba; Ana Maria Vargas Tino; Maria Luisa Ordoñez-Sánchez; Ivette Cruz-Bautista; Carlos A Aguilar-Salinas; Peter Tontonoz; Päivi Pajukanta Journal: J Clin Invest Date: 2011-07-18 Impact factor: 14.808
Authors: Anna C Calkin; Benjamin T Goult; Li Zhang; Louise Fairall; Cynthia Hong; John W R Schwabe; Peter Tontonoz Journal: Proc Natl Acad Sci U S A Date: 2011-11-22 Impact factor: 11.205
Authors: Richard G Lee; Kathryn L Kelley; Janet K Sawyer; Robert V Farese; John S Parks; Lawrence L Rudel Journal: Circ Res Date: 2004-10-14 Impact factor: 17.367
Authors: Vincenzo Sorrentino; Sigrid W Fouchier; Mohammad M Motazacker; Jessica K Nelson; Joep C Defesche; Geesje M Dallinga-Thie; John J P Kastelein; G Kees Hovingh; Noam Zelcer Journal: Eur Heart J Date: 2013-01-16 Impact factor: 29.983
Authors: Marion A M den Boer; Marit Westerterp; Jitske de Vries-van der Weij; Yanan Wang; Lihui Hu; Sonia M S Espirito Santo; Teake Kooistra; Peter Reiss; Johannes A Romijn; Louis M Havekes; Patrick C N Rensen Journal: Atherosclerosis Date: 2009-12-01 Impact factor: 5.162
Authors: Cédric Le May; Jean Mathieu Berger; Anne Lespine; Bruno Pillot; Xavier Prieur; Eric Letessier; M Mahmood Hussain; Xavier Collet; Bertrand Cariou; Philippe Costet Journal: Arterioscler Thromb Vasc Biol Date: 2013-04-04 Impact factor: 8.311
Authors: Daniel I Chasman; Guillaume Paré; Samia Mora; Jemma C Hopewell; Gina Peloso; Robert Clarke; L Adrienne Cupples; Anders Hamsten; Sekar Kathiresan; Anders Mälarstig; José M Ordovas; Samuli Ripatti; Alex N Parker; Joseph P Miletich; Paul M Ridker Journal: PLoS Genet Date: 2009-11-20 Impact factor: 5.917
Authors: Divay Chandra; James Londino; Shaun Alexander; Joseph S Bednash; Yingze Zhang; Robert M Friedlander; Grant Daskivich; Diane L Carlisle; William R Lariviere; Ana Carolina Igami Nakassa; Mark Ross; Claudette St Croix; Toru Nyunoya; Frank Sciurba; Bill Chen; Rama K Mallampalli Journal: J Mol Cell Cardiol Date: 2018-11-16 Impact factor: 5.000
Authors: Stephen D Lee; Christina Priest; Mikael Bjursell; Jie Gao; Douglas V Arneson; In Sook Ahn; Graciel Diamante; J Edward van Veen; Megan G Massa; Anna C Calkin; Jason Kim; Harriet Andersén; Prashant Rajbhandari; Michelle Porritt; Alba Carreras; Andrea Ahnmark; Frank Seeliger; Ingela Maxvall; Pernilla Eliasson; Magnus Althage; Peter Åkerblad; Daniel Lindén; Tracy A Cole; Richard Lee; Helen Boyd; Mohammad Bohlooly-Y; Stephanie M Correa; Xia Yang; Peter Tontonoz; Cynthia Hong Journal: Nat Metab Date: 2019-10-28
Authors: Karin E Bornfeldt; Farah Kramer; Anna Batorsky; Jinkuk Choi; Kelly L Hudkins; Peter Tontonoz; Charles E Alpers; Jenny E Kanter Journal: Am J Pathol Date: 2017-12-15 Impact factor: 4.307
Authors: Anaïs Briot; Mete Civelek; Atsuko Seki; Karen Hoi; Julia J Mack; Stephen D Lee; Jason Kim; Cynthia Hong; Jingjing Yu; Gregory A Fishbein; Ladan Vakili; Alan M Fogelman; Michael C Fishbein; Aldons J Lusis; Peter Tontonoz; Mohamad Navab; Judith A Berliner; M Luisa Iruela-Arispe Journal: J Exp Med Date: 2015-11-09 Impact factor: 14.307